Abstracts tagged "Myositis"

Abstract Number: 1928 • 2012 ACR/ARHP Annual Meeting
Evaluating the Therapeutic Effects of B Cell Depletion Therapy with Rituximab in a Longitudinal Cohort of Mixed Connective Tissue Disease Patients
Ragnar Gunnarsson¹, Inge-Margrethe Gilboe¹, Torhild Garen² and Øyvind Molberg³, ¹Rheumatology unit, Oslo University Hospital Rikshospitalet, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway
Background/Purpose: Even though 40 years have passed since MCTD was defined as a distinct disorder, there is still no evidence based therapy available. The choice…
Abstract Number: 1671 • 2012 ACR/ARHP Annual Meeting
Characterization of Jo-1 Autoantibodies in Patients with Inflammatory Myopathy and Interstitial Lung Disease
Kyle P. Chiang¹, Varun Gauba¹, Darin Lee¹, Minh-Ha T. Do¹, Jie J. Zhou², Feng Wang², Ying Buechler¹, Leslie Nangle¹, Zhiwen Xu², John Mendlein¹, Melissa Ashlock¹ and Jeffrey M. Greve¹, ¹aTyr Pharma, San Diego, CA, ²Scripps Laboratory, Institute for Advanced Study, Hong Kong University of Science and Technology, Kowloon, Hong Kong
Background/Purpose: Anti-Jo-1 autoantibodies (Jo-1 Abs), directed against histidine tRNA synthetase (HisRS1), are detected in a high proportion of patients with both autoimmune inflammatory myopathy (IM)…
Abstract Number: 754 • 2012 ACR/ARHP Annual Meeting
The Functional Index-3 in Adult Dermatomyositis and Polymyositis: Validity and Reliability of an Outcome Measure for Muscle Endurance
Christopher Chong¹, Orla Ni Mhuircheartaigh¹, Helene Alexanderson², Tanaz A. Kermani³, Cynthia S. Crowson⁴, Abigail B. Green⁴, Ann M. Reed⁵ and Floranne C. Ernste⁶, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Dept of Neuroscience, Care Science and Society, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology, University of California Los Angeles, Los Angeles, CA, ⁴Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁵Rheumatology, Mayo Clinic, Rochester, MN, ⁶Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN
Background/Purpose: Although muscle fatigue is a major source of functional impairment in dermatomyositis (DM) and polymyositis (PM), few valid and reliable methods for efficient evaluation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.